Poly Medicure (POLYMED.BO) Earnings Analysis
Poly Medicure (POLYMED.BO) next reports earnings on 2026-07-30, consensus EPS 7.08 INR. Last quarter (2026-05-25) it missed with EPS 6.52 INR vs 8.18 INR est (-20.3%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 51.53.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does POLYMED.BO next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 7.08 INR |
| Revenue estimate | 5.29B |
POLYMED.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-25 | 6.52 INR | 8.18 INR | -20.3% | Miss |
| 2026-02-05 | 7.85 INR | 9.5 INR | -17.4% | Miss |
| 2025-09-30 | 9.06 INR | 9.83 INR | -7.8% | Miss |
| 2025-07-25 | 9.17 INR | 9.2 INR | -0.3% | Miss |
| 2025-02-03 | 8.4 INR | 8.3 INR | +1.2% | Beat |
| 2024-10-28 | 9.01 INR | 8.17 INR | +10.3% | Beat |
Beat rate: 2/6 (33%) over reported quarters with consensus data.
POLYMED.BO valuation and analyst view
| Trailing P/E | 51.53 |
|---|---|
| Trailing EPS | 31.781 INR |
| Price / book | 5.35 |
| Dividend yield | 0.21% |
| Market cap | 169.28B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Poly Medicure (POLYMED.BO)'s next earnings date?
Poly Medicure is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 7.08 INR and revenue estimate of 5.29B.
Did POLYMED.BO beat earnings last quarter?
In its 2026-05-25 report, POLYMED.BO posted EPS of 6.52 INR versus a 8.18 INR estimate — a miss of 20.3%.
What is POLYMED.BO's earnings track record?
Over the last 6 reported quarters with consensus data, POLYMED.BO beat estimates 2 times (33%).
What is POLYMED.BO's current P/E ratio and EPS?
POLYMED.BO trades at a trailing P/E of 51.53 on trailing EPS of 31.780513791878775 INR.
What do analysts rate POLYMED.BO?
POLYMED.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.